• NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine
  • Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package
  • Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan